Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Nov 13;51(21):6916-26.
doi: 10.1021/jm800719t. Epub 2008 Oct 22.

Antibody conjugates of 7-ethyl-10-hydroxycamptothecin (SN-38) for targeted cancer chemotherapy

Sung-Ju Moon  1 , Serengulam V Govindan, Thomas M Cardillo, Christopher A D'Souza, Hans J Hansen, David M Goldenberg
Affiliations

Antibody conjugates of 7-ethyl-10-hydroxycamptothecin (SN-38) for targeted cancer chemotherapy

Sung-Ju Moon et al. J Med Chem. .

Abstract

CPT-11 is a clinically used cancer drug, and it is a prodrug of the potent topoisomerase I inhibitor, SN-38 (7-ethyl-10-hydroxycamptothecin). To bypass the need for the in vivo conversion of CPT-11 and increase the therapeutic index, bifunctional derivatives of SN-38 were prepared for use in antibody-based targeted therapy of cancer. The general synthetic scheme incorporated an acetylene-azide click cycloaddition step in the design, a short polyethylene glycol spacer for aqueous solubility, and a maleimide group for conjugation. Conjugates of a humanized anti-CEACAM5 monoclonal antibody, hMN-14, prepared using these SN-38 derivatives were evaluated in vitro for stability in buffer and human serum and for antigen-binding and cytotoxicity in a human colon adenocarcinoma cell line. Conjugates of hMN-14 and SN-38 derivatives 16 and 17 were found promising for further development.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Size-exclusion HPLC of unmodified hMN-14 (top) and of hMN-14-CL2-SN-38 conjugate with a drug molar substitution of 6.1 (bottom). Unmodified hMN-14 was detected by absorbance at 280 nm. The HPLC profile of the conjugate was detected at the absorbance wavelength of SN-38, namely 360 nm; thus, the peak eluting near the antibody position corresponds to antibody substituted with SN-38. Abbreviation: tR, retention time.
Figure 2
Figure 2
Kinetics of SN-38 release from various hMN-14-SN-38 conjugates incubated in PBS, pH 7.4 (top) or human serum (bottom) at 37 °C. Y-axis displays the ratios of the reverse-phase HPLC peak areas due to SN-38 and the fixed amount of internal standard (10-hydroxycamptothecin) extracted from the incubates. Conjugates: hMN-14-[CL1-SN-38 (7)], square; hMN-14-[CL2-SN-38 (16)], triangle; hMN-14-[CL2-SN-38-10-CO2Et) (17)], inverted triangle; hMN-14-[CL3-SN-38 (21)], diamond; hMN-14-[CL4-SN-38 (25)], X; and hMN-14-[CL5-SN-38 (28)], circle. With hMN-14-21 conjugate, only buffer-stability was determined. The plots were generated using the Prism™ software and the equation for one-phase exponential association [Y = Ymax*(1-exp(-K*X))]. The half-lives, determined as 0.69/K where K is rate constant, are given in Table 2.
Scheme 1
Scheme 1
SN-38, variously derivatized at 10 and 20 positions
Scheme 2
Scheme 2
Synthesis of the bifunctional SN-38, CL-SN-38 (3)
Scheme 3
Scheme 3
Synthesis of the bifunctional SN-38, CL1-SN-38 (7)
Scheme 4
Scheme 4
Synthesis of the bifunctional SN-38, CL2-SN-38 (16) & CL2-SN-38(Et) (17)
Scheme 5
Scheme 5
Synthesis of the bifunctional SN-38, CL3-SN-38 (21)
Scheme 6
Scheme 6
Synthesis of the bifunctional SN-38, CL4-SN-38 (25)
Scheme 7
Scheme 7
Synthesis of the bifunctional SN-38, CL5-SN-38 (28)
Chart 1
Chart 1
Structures of some reagents and structural residues
Chart 2
Chart 2
Structures of bifunctional SN-38 derivatives
See this image and copyright information in PMC

References

    1. Potmesil M. Camptothecins: from bench research to hospital wards. Cancer Res. 1994;54:1431–1439. - PubMed
    1. Sawada S, Okajima S, Aiyama R, Nokata K, Furuta T, Yokokura T, Sugino E, Yamaguchi K, Miyasaka T. Synthesis and antitumor activity of 20(S)-camptothecin derivatives: carbamate-linked, water-soluble derivatives of 7-ethyl-10-hydroxycamptothecin. Chem. Pharm. Bull. (Tokyo) 1991;39:1446–1450. - PubMed
    1. Rivory LP, Bowles MR, Robert J, Pond SM. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. Biochem. Pharmacol. 1996;52:1103–1111. - PubMed
    1. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 1991;51:4187–4191. - PubMed
    1. Rougier P, Bugat R. CPT-11 in the treatment of colorectal cancer: Clinical efficacy and safety profile. Seminars Oncol. (suppl. 3) 1996;23:34–41. - PubMed

Publication types

MeSH terms